Literature DB >> 34184117

Cationic Polyelectrolyte Nanocapsules of Moxifloxacin for Microbial Keratitis Therapy: Development, Characterization, and Pharmacodynamic Study.

Parasuraman Mohan1, Karthikeyan Kesavan2.   

Abstract

Microbial keratitis (MK) is a vision-threatening disease and the fourth leading cause of blindness worldwide. In this work, we aim to develop moxifloxacin (MXN)-loaded chitosan-based cationic mucoadhesive polyelectrolyte nanocapsules (PENs) for the effective treatment of MK. PENs were formulated by polyelectrolyte complex coacervation method and characterized for their particle size, surface charge, morphology, mucoadhesive property, in-vitro and ex-vivo release, ocular tolerance, and antimicrobial efficacy studies. The pharmacodynamic study was conducted on rabbit eye model of induced keratitis and it is compared with marketed formulation (MF). Developed PENs showed the size range from 230.7 ± 0.64 to 249.0 ± 0.49 nm and positive surface charge, spherical shape along with appropriate physico-chemical parameters. Both in-vitro and ex-vivo examination concludes that PENs having more efficiency in sustained release of MXN compared to MF. Ocular irritation studies demonstrated that no corneal damage or ocular irritation. The in-vivo study proved that the anti-bacterial efficacy of PENs was improved when compared with MF. These results suggested that PENs are a feasible choice for MK therapy because of their ability to enhance ocular retention of loaded MXN through interaction with the corneal surface of the mucous membrane.

Entities:  

Keywords:  Chitosan; Gellan; Microbial keratitis; Moxifloxacin; Mucoadhesive; Polyelectrolyte nanocapsules

Mesh:

Substances:

Year:  2021        PMID: 34184117     DOI: 10.1208/s12249-021-02039-1

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  30 in total

Review 1.  Management of bacterial keratitis: beyond exorcism towards consideration of organism and host factors.

Authors:  T P O'Brien
Journal:  Eye (Lond)       Date:  2003-11       Impact factor: 3.775

Review 2.  Polymeric nanoparticulate system: a potential approach for ocular drug delivery.

Authors:  Ramesh C Nagarwal; Shri Kant; P N Singh; P Maiti; J K Pandit
Journal:  J Control Release       Date:  2009-02-03       Impact factor: 9.776

Review 3.  Nanotherapies for the treatment of ocular diseases.

Authors:  S Reimondez-Troitiño; N Csaba; M J Alonso; M de la Fuente
Journal:  Eur J Pharm Biopharm       Date:  2015-02-26       Impact factor: 5.571

4.  Chitosan-gellan electrostatic complexes: influence of preparation conditions and surfactant presence.

Authors:  Carolina Siqueira Franco Picone; Rosiane Lopes Cunha
Journal:  Carbohydr Polym       Date:  2013-02-07       Impact factor: 9.381

Review 5.  Update on the Management of Infectious Keratitis.

Authors:  Ariana Austin; Tom Lietman; Jennifer Rose-Nussbaumer
Journal:  Ophthalmology       Date:  2017-09-21       Impact factor: 12.079

Review 6.  Moxifloxacin.

Authors:  J A Balfour; L R Wiseman
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

7.  Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Authors:  E Pestova; J J Millichap; G A Noskin; L R Peterson
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

Review 8.  Recent development of chitosan-based polyelectrolyte complexes with natural polysaccharides for drug delivery.

Authors:  Yangchao Luo; Qin Wang
Journal:  Int J Biol Macromol       Date:  2013-12-17       Impact factor: 6.953

9.  Pectin-coated chitosan-LDH bionanocomposite beads as potential systems for colon-targeted drug delivery.

Authors:  Lígia N M Ribeiro; Ana C S Alcântara; Margarita Darder; Pilar Aranda; Fernando M Araújo-Moreira; Eduardo Ruiz-Hitzky
Journal:  Int J Pharm       Date:  2013-12-27       Impact factor: 5.875

10.  Second harmonic generation imaging of corneal stroma after infection by Pseudomonas aeruginosa.

Authors:  Danielle M Robertson; Nathan A Rogers; W Matthew Petroll; Meifang Zhu
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.